SOURCE: The Bedford Report

The Bedford Report

September 05, 2011 08:16 ET

Big Pharma Turns to New Revenue Drivers as Patent Cliffs Loom

The Bedford Report Provides Equity Research on Pfizer & Merck

NEW YORK, NY--(Marketwire - Sep 5, 2011) - With several patent cliffs looming, companies in the Drug Manufacturing sector are adopting different strategies to ensure their own health once several drugs open up to generic copies. One major trend has been to focus on emerging healthcare markets where growth is strong in order to help offset upcoming domestic uncertainty. The Bedford Report examines investing opportunities in the Drug Manufacturers - Major industry and provides stock research on Pfizer, Inc. (NYSE: PFE) and Merck & Co. (NYSE: MRK). Access to the full company reports can be found at:

Future growth of the pharmaceutical industry is expected to take place in emerging markets including India, China, Brazil, South Africa and others. This is because the economies of these countries are booming and the middle class in these nations continues to rapidly grow. "Emerging market activity will be a source of out-performance for pharma stocks," thinks Dr Gbola Amusa, Managing Director, Global Pharmaceuticals Sector Co-ordinator and Head of European Pharmaceuticals Research at UBS. "Emerging markets for pharma are now just big enough to matter," said Dr Amusa. "They are up from 5% of [Big Pharma's] business five years ago to 20-30 percent."

Merck has said that it has "significantly reduced" the number of sales reps in developed markets. The company's goal is to grow sales in emerging markets from 18 percent to 25 percent by 2013.

The Bedford Report releases equity research on the Drug Manufacturers - Major industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Over the last three years, Pfizer has put forth plans to capture greater revenues in emerging markets. Back in 2008, the company said that it plans to increase its market share in Asia by 2 percent -- reaching 6 percent -- by 2012.

Last month Pfizer announced that it has prevailed in its Viagra patent infringement action against Teva Pharmaceuticals. The court's decision, which is subject to appeal, prevents Teva from receiving approval for a generic form of Viagra until October 2019.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

Contact Information